Bispecific Antibodies in Cancer Immunotherapy

The present and future of bispecific antibodies for cancer therapy

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic applications that cannot be achieved using conventional ...

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response ...

Among all the antibody-centered cancer therapy, T-cell engaging bispecific antibodies (T-biAbs) have a promising role in future cancer ...

Bispecific antibodies: advancing precision oncology: Trends in Cancer

Bispecific antibodies (bsAbs) offer a novel approach to anticancer therapy by targeting different antigens via a range of mechanisms of action.

Bispecific antibodies in cancer therapy: Target selection and ...

The FDA first issued draft guidance for Bispecific Antibody Development Programs on April 19, 2019, followed by a final version on May 24, 2021.

Current landscape and future directions of bispecific antibodies in ...

Bispecific antibodies (BsAbs) are dual-specificity molecules binding two different epitopes simultaneously, the concept of which has been first described ...

Efficacy and safety of bispecific antibodies vs. immune checkpoint ...

In recent years, bispecific antibodies (BSABs) have emerged as a novel strategy in tumor immunotherapy. BSABs combine two distinct antigen ...

Bispecific Antibody Immunotherapy - Cancer Support Community

Get a simple explanation of how bispecific antibody drugs work to help the immune system fight cancer cells and learn about possible side effects.

Bispecifics antibodies: The next big thing in lymphoma treatment

These bispecific antibodies treat cancer by engaging the tumor-specific antigen CD20 and the CD3 antigen on T cells. "Bispecifics allows us to ...

Bispecific antibodies: advancing precision oncology - ScienceDirect

Current management involves rituximab plus high-dose chemotherapy, autologous stem cell transplantation, and chimeric antigen receptor (CAR)-T therapy. Despite ...

Bispecific Antibodies - BC Cancer

Bispecific antibodies engaging T-cells have emerged as an innovative form of immunotherapy, seamlessly combining two antigen-recognizing elements into a single ...

'Switchable' bispecific antibodies pave way for safer cancer treatment

Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that ...

Targeted Antibodies Immunotherapy - CRI - Cancer Research Institute

Some bispecific antibodies, known as bispecific T cell engagers, or BiTEs, target both cancer cells and immune cells known as T cells. These BiTEs work to bring ...

Emerging bispecific antibodies in cancer immunotherapy

As part of an effort to increase antibody efficacy, bispecific antibodies (bsAbs), which can bind two different antigens or epitopes are ...

unleashing the potential of bispecific antibodies for targeted treatment

Recent progressions in immunotherapy have transformed cancer treatment, providing a promising strategy that activates the immune system of the patient to find ...

Double hit — bispecific antibodies in cancer therapy | Bogdanowicz

Abstract. Immunotherapy has emerged as a promising strategy for cancer treatment, with bispecific antibodies (BsAbs) demonstrating significant ...

Bispecific Antibodies for Cancer Immunotherapy

Bispecific immunotherapeutic biologics offer tremendous potential to improve clinical efficacy and safety by targeting two different antigens in immune and ...

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy

These molecules, here referred to as bispecific immunomodulatory antibodies, have the potential to improve clinical efficacy and safety profile and are ...

Bispecific antibody - AstraZeneca

Bispecific antibodies are engineered to bind to two different epitopes, or antigens, (the part of the target that the antibody attaches to) at the same time.

Recent advances and challenges of bispecific antibodies in solid ...

Bispecific antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody-target cancer immunotherapy, which ...

Bispecific antibodies for cancer therapy: A review - ScienceDirect.com

There are over 50 bispecific antibodies currently on clinical trials for various malignancies and the hope is that in the future many of these, with better ...